ASLAN Pharmaceuticals Limited (NASDAQ:ASLN) Sees Large Growth in Short Interest

ASLAN Pharmaceuticals Limited (NASDAQ:ASLN) was the target of a large growth in short interest in April. As of April 15th, there was short interest totalling 250,200 shares, a growth of 114.2% from the March 31st total of 116,800 shares. Based on an average trading volume of 1,170,000 shares, the days-to-cover ratio is presently 0.2 days. Approximately 1.5% of the company’s stock are short sold.

Wall Street Analyst Weigh In

Several brokerages recently commented on ASLN. Piper Sandler restated an “overweight” rating and set a $10.00 target price (down previously from $15.00) on shares of ASLAN Pharmaceuticals in a report on Wednesday, March 13th. HC Wainwright reiterated a “buy” rating and set a $9.00 price target on shares of ASLAN Pharmaceuticals in a research report on Tuesday.

ASLAN Pharmaceuticals Stock Down 4.7 %

ASLAN Pharmaceuticals stock opened at $0.45 on Friday. The company has a market capitalization of $7.32 million, a PE ratio of -0.16 and a beta of 1.45. The firm’s fifty day moving average is $0.60 and its 200 day moving average is $0.72. ASLAN Pharmaceuticals has a 12-month low of $0.39 and a 12-month high of $4.69.

ASLAN Pharmaceuticals (NASDAQ:ASLN) last announced its quarterly earnings data on Friday, April 12th. The company reported ($0.78) earnings per share for the quarter. Sell-side analysts expect that ASLAN Pharmaceuticals will post -2.68 EPS for the current fiscal year.

ASLAN Pharmaceuticals Company Profile

ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises ASLAN004, a monoclonal antibody that targets the IL-13 receptor a1 subunit which is being developed for the treatment of atopic dermatitis and other immunology indications; and ASLAN003, a small-molecule inhibitor of dihydroorotate dehydrogenase for the treatment of autoimmune diseases.